Don't give up! 2020 glioblastoma is worth looking forward to the study progress inventory.

Glioblastoma, also known as polymorphic glioblastoma, is one of the most common and invasive brain cancers.
the tumor grows very rapidly and has a very poor prognostication, and clinical outcomes in GBM patients have barely improved in the last three decades: the standard treatment is chemotherapy and radiation therapy after surgery.
drugs are often used as chemotherapy for glioblastoma.
Even if the surgical removal was clean, the average time to the recurrence of the tumor was only 6.9 months, the average survival time was only 14.6 months, and the average total survival time was only 14.7 to 16.6 months with thymosamine and radiotherapy aids.
signs and symptoms of glioblastoma were initially nonse specific.
may experience headaches, personality changes, nausea, stroke-like symptoms, and symptoms usually worsen rapidly and may develop into confusion.
The reasons for the difficulty of treating glioblastoma are two: First, because glioblastoma will be immersed in normal brain tissue, tumors and normal brain tissue often lack clear boundaries, surgery and radiotherapy is difficult to determine the scope, so it is impossible to completely remove them.
, because the brain has a protective layer called the blood-brain barrier, so most anti-cancer drugs can not reach the site of the brain tumor.
clinically urgent need for new treatments.
let's see what new treatments around the world in 2020 may give patients new hope," he said.
, targeted treatment for nearly three decades, newly diagnosed glioblastoma patients do not have any new drug treatment, tymoamine is the only option.
years, the targeted treatment of brain tumors has made a major breakthrough.
1, the new drug Paxalisib into the first-line treatment! Is it expected to replace moramine? Recently, data were released in the interim positive phase of the paxalisib (codenium GDC-0084) treatment of polygonal glioblastoma (GBM) Phase II study (NCT03522298).
paxalisib is a small molecule inhibitor that can cross the blood-brain barrier in the PI3K/AKT/mTOR path, and is currently being developed to treat the most common and invasive primary brain cancer, glioblastoma.
Y. Wen, a professor of neurology at Harvard Medical School and a professor at the Dana Faber Cancer Institute, says a new treatment for glioblastoma is imminent.
GDC-0084 has the potential to be an important new drug for this challenging disease.
in a Phase II clinical trial, the clinical effects of paxalisib as an auxiliary treatment are being evaluated after the initial release of chemotherapy by patients with surgical excision and temomolomede (temozolomide, TMZ).
(1) medium total lifetime (OS) was 17.7 months, representing clinically significant life extension compared to the 12.7 months associated with the existing standard nursing tymoamine.
(2) medium non-progressed lifetime (PFS) was 8.5 months, representing a significant extension of survival compared to the 5.3 months associated with the existing standard care of termoazine.
(3) who received the longest treatment remained disease-free 19 months after diagnosis.
(4) about half of the patients in the group are still receiving paxalisib treatment, and OS and PFS data are likely to improve further as research continues.
2, MAPK important signaling path - BRAF inhibitors in children with fewer genetic mutations in low-level glioma, MAPK signaling path is the main source of mutation, BRAF gene is an important component in mapK signaling path, in the development of glioma plays an important role.
2017, a Canadian study found that patients with low-grade childhood gliomas with BRAF V600E mutations were insensitive to conventional chemotherapy, with a 10-year progression-free survival rate (PFS) of 27 percent, while BRAF wild PFS was 60.2 percent.
6 patients with BRAF V600E mutations used BRAF inhibitors after the progression of conventional treatment of the disease, with a significant response, tumor reduction of 49% to 80% (shown in the red box below), and the follow-up of these 6 patients took the drug for an average of 18.5 months, during which time the disease stabilized.
combination of BRAF inhibitors with specific drug combinations such as EGFR and Axl inhibitors may benefit most from patients with gliomas with BRAF V600E mutations.
3, MAPK important signaling path - MET inhibitors in children's collagen fusion of the more common carcinogenic gene fusion of about 10%, met gene fusion as a typical, the following image left is the type of MET gene fusion.
met fusion activates the MAPK signaling path, disrupts cell cycle regulation, and induces tumor progression.
of met inhibitors have found that they inhibit the growth of tumors with MET mutations.
4, "Diamond" target gene - NTRK since 2018, the world's first unlimited cancer target drug - LaRotini, another "diamond" target gene - NTRK quickly spread the cancer circle.
statistics, the frequency of NTRK fusion in brain tumors in children and adults is very different, between 3 and 40%, the most common polymorphic glioblastoma is NTRK2 fusion.
currently on the market for NTRK Fusion include Larotrectinib and Entrectinib, as well as Selletrectinib (LOXO-195/BAY-2731954; NCT03206931) in clinical trials NCT03215511) and Repotrectinib (TPX-0005; NCT04094610, NCT03093116), almost every one is a "cure system" specialty, the efficacy is worth looking forward to.
2. Immunotherapy glioblastoma is called an immune "cold" tumor because the brain tumor contains very few immune cells, and there is a system in the brain called the blood-brain barrier that prevents T cells from entering the brain tissue, which is very difficult to produce an immune response to the tumor.
PD-1, the anti-cancer drug, is at a risk, and scientists have been looking for effective immunotherapy to break the bottleneck.
1, first confirmed: PD-1 preoperative use can double survival A new study from the Dana-Farber Cancer Institute and the University of California, Los Angeles (UCLA) suggests that immunotherapy may work best in new complementary treatments before surgery.
randomized study, which included 35 patients, had encouraging results, with patients receiving immunotherapy before and after surgery, and patients with relapsed glioblastoma living almost twice as long as those receiving immunotherapy drugs after surgery! The study will be published in march in the international heavyweight journal Nature Medicine.
2, the dawn of the new dendracyte vaccine on April 8, 2020, the new dendratic cell therapy AV-GBM-1 Phase II clinical trial data released, the study showed that this new vaccine to extend the new diagnosis of glioblastoma patients in the medium-term overall survival show great potential.
the total survival rate of 15 months was 76% for 50 patients treated with AV-GBM-1, compared with 61% for 12 months and 48% for 287 patients in the control group who received standard treatment.
showed that the overall survival rate of patients treated with AV-GBM-1 increased by 28% over a 15-month period, with particularly significant results.
AV-GBM-1 is a patient's own specific degenerative cell vaccine designed to use the patient's own immune system to find and eliminate cancer cells this dexterous cell vaccine can carry the specific antigen information extracted from postoperative tumor tissue, after injection, the antigen information transmitted to T cells, stimulate tumor killing activity.
The patient-specific self-vaccine, while logically complex, is a viable method that can be carried out simultaneously with tymoamine and radiation therapy, or it can be recovered from chemotherapy and radiotherapy before being vaccinated against AV-GBM-1.
patients under the age of 70 are eligible to participate in the study if they are able to successfully collect single white blood cells.
3. Virus therapy for poisoning: Lysovirus - PVSRIPO Scientists at Duke University Cancer Research Institute in the United States used poliovirus (PVSRIPO) to significantly prolong the lives of patients with cerebroglioblastoma, a weighty study published in the leading medical journal, the New England Journal of Medicine (NEJM), which attracted widespread medical attention.
as of March 20, 2018, 8 patients responded to treatment, 2 patients with glioma lesions completely disappeared, reached complete remission! Currently, PVSRIPO is conducting Phase II clinical trials at several well-known cancer centers in the United States, including Massachusetts General Hospital and the Dana Faber Cancer Institute, and is still being recruited.
Summary: Although glioblastoma is the most common malignant tumor, 5 years relative survival rate of only 6.8%, but I believe that in the near future will emerge more and more new treatment technologies and new drugs for resuscable glioblastoma, and the various new research mentioned in this article will not stop here, we look forward to more and more unexpected clinical research results in the future.
Zhihao Zhang Zhihao, President of Fuji International Health Management Co., Ltd., Japan, was established in 2015 as a medical professional services organization in Japan.
2018 through the Japanese Ministry of Foreign Affairs, Ministry of Economy, Trade and Industry joint certification, the Ministry of Foreign Affairs medical visa guarantee agency, the Ministry of Economy, Trade and Industry cross-border medical support enterprises.
based in Japan, looking at the world, with many top medical resources, to provide customers with international advanced medical technology VIP fast track.
We adhere to the path of specialization, by the local health care license Chinese people to form your private medical support team, and provide patients with food and clothing to support the full range of life support Zhang Zhihao Source: Fuji Health Information !-- content display end - !-- to determine whether the login ends.